Biotechnology

Salarius Pharmaceuticals

Salarius Pharmaceuticals released FY2025 Q3 earnings on November 14 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -1.8137 (forecast USD -706.7996)

Salarius Pharmaceuticals released FY2025 9 Months Earnings on November 14, 2025 (EST) with actual revenue of USD 0 and EPS of USD -1.8137

Salarius Pharmaceuticals released FY2025 Semi-Annual earnings on August 12 (EST) with actual revenue of USD 0 and EPS of USD 0

Salarius Pharmaceuticals released FY2025 Q2 earnings on August 12 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -0.4511 (forecast USD -46.8)

Salarius Pharmaceuticals Conducting Seclidemstat Clinical Trial for MDS and CMML Patients

Salarius Updates Merger Agreement with Decoy

Salarius Pharmaceuticals released FY2025 Q1 earnings on May 14 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD 0 (forecast USD -701.9996)

Salarius Pharma Reports $5.6 Million Net Loss in 2024, Considering Merger with Decoy Therapeutics

Salarius Pharmaceuticals released FY2024 Q4 earnings on March 21 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD 0 (forecast USD -805.20)

Salarius Pharmaceuticals released FY2024 annual earnings on March 21 (EST), actual revenue 0 USD (forecast 0 USD), actual EPS -5.7947 USD (forecast -214.48 USD)

Salarius Pharmaceuticals released FY2024 Cumulative 3Q Earnings on November 14 (EST), Revenue: 0, EPS: -6.4021

Salarius Pharmaceuticals released FY2024 Q3 earnings on November 14 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -11.3754 (forecast USD -803.9996)

Salarius Pharmaceuticals released FY2024 Q2 earnings on August 9 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD 0 (forecast USD -803.9996)

Salarius Pharmaceuticals released FY2024 Semi-Annual earnings on August 9 (EST) with actual revenue of USD 0 and EPS of USD 0

Salarius Pharmaceuticals Decides to Close Seclidemstat Clinical Trial for Ewing Sarcoma

Salarius Pharmaceuticals: FDA to partially pause clinical trial evaluating the combination of Seclidemstat (SP-2577) and Azacitidine

Salarius Pharmaceuticals released FY2024 Q1 earnings on May 13 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD 0 (forecast USD -803.9996)

Salarius Pharmaceuticals released FY2023 Q4 earnings on March 22 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD 0 (forecast USD -178.80)

Salarius Pharmaceuticals released FY2023 earnings on March 22 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD 0 (forecast USD -791.9996)

Salarius Pharmaceuticals released FY2023 9 Months Earnings on November 9, 2023 (EST) with actual revenue of USD 0 and EPS of USD 0

SMX Security Matters

Gulf Resources

Treasure Gbl

Wheeler Real Estate

Dreamland

Irobot

Praxis Precision Medicines

DigitalBridge

Urgently

AiRWA

Please note that a "Suspected value trap" is a stock that appears The stock looks financially sound and severely undervalued, but behind the low valuation is a long-term decline in business capacity or a serious financial crisis, or even the risk of bankruptcy in the short term.

Suspected value trap